Results 51 to 60 of about 424 (108)
Supine plasma NE predicts the pressor response to droxidopa in neurogenic orthostatic hypotension [PDF]
Neurology, 2018 To test whether the plasma levels of norepinephrine (NE) in patients with neurogenic orthostatic hypotension (nOH) predict their pressor response to droxidopa.This was an observational study, which included patients with nOH. All patients had standardized autonomic function testing including determination of venous plasma catecholamine levels drawn ...
Horacio Kaufmann +3 more
openaire +3 more sources
Health Science Reports, 2021 Patients with neurogenic orthostatic hypotension (nOH) due to autonomic dysfunction may also experience supine hypertension (defined as supine systolic blood pressure [SBP] ≥140 mmHg).
L. Hewitt +5 more
semanticscholar +1 more source
Neurogenic orthostatic hypotension – management update and role of droxidopa
Therapeutics and Clinical Risk Management, 2015 Orthostatic hypotension (OH) is defined as a significant decrease in blood pressure (BP) during the first 3 minutes of standing or a head up on a tilt table. Symptoms of OH are highly variable, ranging from mild light-headedness to recurrent syncope.
Vivek Sharma, Joy Vijayan
openaire +4 more sources
Impact of the Norepinephrine Prodrug Droxidopa on the QTc Interval in Healthy Individuals [PDF]
Clinical Pharmacology in Drug Development, 2017 AbstractA double‐blind, 4‐period crossover study (NCT01327066) was conducted to assess the effect of the novel norepinephrine prodrug droxidopa on the QT interval in in healthy subjects. Subjects were randomized to receive a single dose of droxidopa 600 mg (maximal dose) and 2000 mg (supratherapeutic dose) compared with the positive control ...
L. Arthur Hewitt +2 more
openaire +3 more sources
Droxidopa for neurogenic orthostatic hypotension [PDF]
Neurology, 2014 To determine whether droxidopa, an oral norepinephrine precursor, improves symptomatic neurogenic orthostatic hypotension (nOH).Patients with symptomatic nOH due to Parkinson disease, multiple system atrophy, pure autonomic failure, or nondiabetic autonomic neuropathy underwent open-label droxidopa dose optimization (100-600 mg 3 times daily), followed,
Christopher J. Mathias +9 more
openaire +2 more sources
Analytical SciencesThe electrochemical behavior of catecholamines involves an electron transfer-chemical reaction-electron transfer (ECE) mechanism, characterized by two reversible redox reactions interspersed with an irreversible chemical reaction. Previously, we reported
Yoka Shu, Mei Kadowaki, Hitoshi Muguruma
semanticscholar +1 more source
Journal of Medical Case Reports, 2020 Background Droxidopa is an oral treatment for the stepwise treatment of neurogenic orthostatic hypotension from autonomic dysfunction. It has been shown to be useful predominantly with neurogenic orthostatic hypotension secondary to Parkinson’s disease ...
Annie H. Ho +4 more
semanticscholar +1 more source
, 2020 A novel electrochemical sensor for the selective and sensitive detection of droxidopa in presence of carbidopa at physiological pH was developed by the bulk modification of carbon paste electrode (CPE) with copper oxide (CuO), ionic liquid and Mn (III ...
Mohammad Reza Aflatoonian +5 more
semanticscholar +1 more source
Vascular Health and Risk Management, 2014 Neurogenic orthostatic hypotension (nOH) is due to failure of the autonomic nervous system to regulate blood pressure in response to postural changes due to an inadequate release of norepinephrine, leading to orthostatic hypotension and supine hypertension. nOH is common in Parkinson's disease (PD).
Stuart Isaacson, Julia Skettini
openaire +3 more sources